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The existence of a non-lysosomal glucosylceramidase
in human cells has been documented (van Weely, S.,
Brandsma, M., Strijland, A., Tager, J. M., and Aerts,
J. M. F. G. (1993) Biochim. Biophys. Acta 1181, 55–62).
Hypothetically, the activity of this enzyme, which is lo-
calized near the cell surface, may influence ceramide-
mediated signaling processes. To obtain insight in the
physiological importance of the non-lysosomal glucosyl-
ceramidase, the availability of specific inhibitors would
be helpful. Here we report on the generation of hydro-
phobic deoxynojirimycin (DNM) derivatives that po-
tently inhibit the enzyme. The inhibitors were designed
on the basis of the known features of the non-lysosomal
glucosylceramidase and consist of a DNM moiety, an
N-alkyl spacer, and a large hydrophobic group that pro-
motes insertion in membranes. In particular, N-(5-ada-
mantane-1-yl-methoxy)pentyl)-DNM is a very powerful
inhibitor of the non-lysosomal glucosylceramidase at
nanomolar concentrations. At such concentrations, the
lysosomal glucocerebrosidase and a-glucosidase, the
glucosylceramide synthase, and the N-linked glycan-
trimming a-glucosidases of the endoplasmic reticulum
are not affected.
In recent years, the importance of ceramide as a second
messenger has been recognized. It has become clear that the
signal of some cytokines is mediated by changes in the intra-
cellular concentration of this lipid (1, 2). For example, local
changes in ceramide concentration in specific regions of the
plasma membrane are crucial for the transduction of the signal
exerted by tumor necrosis factor-a . Upon binding of the cyto-
kine to its receptor, a sphingomyelinase catalyzes the conver-
sion of sphingomyelin into phosphorylcholine and ceramide.
The ceramide that is generated in this manner propagates the
signal by activating specific protein kinases and phosphatases,
resulting in the cellular response. This mechanism has been
substantiated by the demonstration that the effects of tumor
necrosis factor-a can be experimentally mimicked by the ad-
ministration of a permeable ceramide with a truncated fatty
acyl moiety or, alternatively, by the generation of ceramide at
the cell surface by treatment of cells with a bacterial sphingo-
myelinase (see, for example, Ref. 2).
In the plasma membrane of cells, considerable amounts of
ceramide are present as a building block in sphingomyelin and
also in glycosphingolipids such as glucosylceramide. The latter
lipids are not believed to play a role in ceramide-mediated
signal transduction since their catabolism is thought to occur
exclusively in lysosomes. The importance of intralysosomal
glycosphingolipid catabolism is illustrated by the existence of
inherited lysosomal storage disorders in which specific glyco-
sphingolipids accumulate as the consequence of an inherited
defect in some lysosomal glycosidases. One of the most common
lipidoses is Gaucher’s disease, a disorder caused by a deficiency
in the lysosomal acid b-glucosidase, glucocerebrosidase1 (EC
3.2.1.45), which hydrolyzes glucosylceramide into free glucose
and ceramide (3). We discovered the existence of a non-lysoso-
mal glucosylceramidase activity that is located near the cell
surface (4). Besides its distinct subcellular localization, the
non-lysosomal glucosylceramidase differs clearly in other as-
pects from the lysosomal glucocerebrosidase (4). In contrast to
the latter enzyme, it is an integral membrane protein that is
not deficient in Gaucher’s disease patients. The two enzymes
are also clearly distinct in their specificity toward artificial
substrates, inhibitors, and activators (4). For example, the
non-lysosomal glucosylceramidase is not able to hydrolyze ar-
tificial b-xylosidic substrates, contrary to glucocerebrosidase.
Glucocerebrosidase is irreversibly inhibitable by conduritol B
epoxide, in contrast to the glucosylceramidase, which is rela-
tively insensitive to this compound. The lysosomal activator
protein saposin C potently stimulates glucocerebrosidase in its
enzyme activity, but is without effect on the non-lysosomal
glucosylceramidase (4).
Earlier experiments with membrane suspensions have re-
vealed that the ceramide that is formed by the non-lysosomal
glucosylceramidase is efficiently converted into sphingomyelin,
presumably by transfer of the phosphorylcholine moiety from
phosphatidylcholine (4). The activity of the non-lysosomal glu-
cosylceramidase might therefore result in (transient) changes
in glucosylceramide, ceramide, phosphorylcholine, diacylglyc-
erol, and sphingomyelin concentrations. Because of its localiza-
tion close to the cell surface, a direct or indirect role for the
non-lysosomal glucosylceramidase in the sphingolipid metabo-
lism linked to ceramide-mediated signaling processes might be* The costs of publication of this article were defrayed in part by thepayment of page charges. This article must therefore be hereby marked
“advertisement” in accordance with 18 U.S.C. Section 1734 solely to
indicate this fact.
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envisioned. To investigate this intriguing possibility, we have
now developed novel specific inhibitors for the non-lysosomal
glucosylceramidase. For this purpose, the available informa-
tion on the membrane-bound feature of the enzyme and its
relatively high affinity for inhibition by deoxynojirimycin-type
compounds has been exploited. Here we report on the design,
synthesis, and application of hydrophobic deoxynojirimycin an-
alogues as specific inhibitors for the non-lysosomal glucosylce-
ramidase. The value of these inhibitors as research tools in the
elucidation of the physiological relevance of the non-lysosomal
glucosylceramidase is discussed.
EXPERIMENTAL PROCEDURES
Synthesis of Inhibitors
All reagents used for synthesis of the deoxynojirimycin derivatives
were from Aldrich, except tetra-O-benzylglucopyranose, which was ob-
tained from Sigma. Deoxynojirimycin (DNM)2 was prepared from tetra-
O-benzylglucopyranose according to the literature procedure (5). N-
Propyl-, N-butyl-, N-pentyl-, and N-heptyl-DNM were prepared by
literature procedure (6–8) by treatment of DNM HCl with the appro-
priate aldehyde under the agency of sodium cyanoborohydride and
acetic acid. N-Pentanoyl-DNM was prepared by condensation of the
known 2,3,4,6-tetra-O-benzyl-DNM (5) with valeryl chloride and sub-
sequent hydrogenolysis of the benzyl ethers catalyzed by palladium on
carbon. The N-acylated DNM derivatives containing adamantane-
methyl, adamantanyl, phenantryl, cholesteryl, and b-cholestanyl sub-
stituents were prepared as follows. Glutaric anhydride was treated
with 4-nitrophenol to afford pentanedioic acid mono-(4-nitrophenyl)
ester. Treatment with oxalyl chloride under the agency of a catalytic
amount of dimethylformamide afforded the corresponding 4-chlorocar-
bonylbutyric acid 4-nitrophenyl ester, which was subsequently con-
densed with adamantanemethanol, adamantanol, phenantrol, choles-
terol, or b-cholestanol to afford 4-adamantanemethylcarbonylbutyric
acid 4-nitrophenyl ester, 4-adamantanecarbonylbutyric acid 4-nitro-
phenyl ester, 4-phenantrylcarbonylbutyric acid 4-nitrophenyl ester,
4-cholesterylcarbonylbutyric acid 4-nitrophenyl ester, and 4b-cholesta-
nylmethylcarbonylbutyric acid 4-nitrophenyl ester. Condensation of
these esters with 2,3,4,6-tetra-O-benzyl-DNM and subsequent palladi-
um/carbon-mediated hydrogenolysis afforded N-(4-adamantanemetha-
nylcarboxy-1-oxo)-DNM, N-(4-adamantanylcarboxy-1-oxo)-DNM, N-(4-
phenantrylcarboxy-1-oxo)-DNM, N-(4-cholesterylcarboxy-1-oxo)-DNM,
and N-(4-b-cholestanylcarboxy-1-oxo)-DNM, respectively. Alterna-
tively, the N-alkylated DNM derivatives containing adamantanemethyl
and cholesteryl substituents were prepared by reduction of the known
glutaric dialdehyde mono(diethyl)acetal to 5,5-diethoxypentan-1-ol (9),
which was transformed to the corresponding methanesulfonic acid 5,5-
diethoxypentyl ester by treatment with methanesulfonyl chloride and
triethylamine. Condensation with adamantanemethanol and choles-
terol, respectively, under the agency of sodium hydride and subsequent
liberation of the aldehyde functionality afforded 5-(adamantan-1-yl-
methoxy)pentanal and 5-(cholesteroloxy)pentanal, which were con-
densed with DNM under reductive amination conditions (sodium cya-
noborohydride and acetic acid) to afford N-(5-adamantane-1-yl-
methoxy)pentyl)-DNM (AMP-DNM) and N-(5-cholesteroxypentyl)-
DNM (CP-DNM). The structures of these compounds are shown in Fig.
1.
Preparation of Spleen Extract and Membrane Suspension
Water extracts of Gaucher’s disease and normal spleens were pre-
pared by homogenization of 10 g of tissue in 30 ml of water (4 °C) using
an Ultra-Turrax and centrifugation for 20 min at 15,000 3 g. The
membrane suspensions were prepared by resuspending the pellet in 30
ml of 50 mM potassium phosphate buffer (pH 5.8) and centrifugation (15
min, 15,000 3 g). This procedure was repeated two times.
Enzyme Assays
All 4-methylumbelliferyl (4-MU) substrates used were obtained from
Sigma. The activity of Ceredase® (Genzyme, Boston, MA) was deter-
mined with 3 mM 4-MU b-glucoside in the presence of 0.25% (w/v)
sodium taurocholate and 0.1% (v/v) Triton X-100 in McIlvaine buffer
(0.1 M citrate and 0.2 M phosphate buffer) (pH 5.2). The activity of the
lysosomal glucocerebrosidase in splenic membrane suspensions was
determined with 3 mM 4-MU b-glucoside in McIlvaine buffer (pH 5.2).
The activity of the non-lysosomal glucosylceramidase in membrane
suspensions was determined with 3 mM 4-MU b-glucoside in McIlvaine
buffer (pH 5.8) upon preincubation for 30 min at room temperature with
2.5 mM conduritol B epoxide (CBE) (Sigma). The activity of the lysoso-
mal a-glucosidase was measured with 0.3 mM 4-MU a-glucoside in 125
mM sodium acetate buffer (pH 4.0). IC50 values were determined by
variation of inhibitor concentrations. Assays were incubated at 37 °C
and stopped by the addition of glycine/NaOH (pH 10.6). The amount of
liberated 4-MU was determined with a Perkin-Elmer LS2 fluorometer.
In Vivo Inhibition Experiments
Melanoma Cells—Human melanoma cells were cultured in RPMI
1640 medium (Flow Laboratories) supplemented with 5% fetal calf
serum (Hyclone Laboratories). The enzyme activities were measured as
described previously (4). In short, melanoma cells were incubated with
5 mM 4-MU b-glucoside in phosphate-buffered saline in the absence or
presence of various DNM inhibitors. To distinguish between the contri-
butions by both the lysosomal and non-lysosomal enzymes, the experi-
ments were performed in parallel with melanoma cells that had been
preincubated with and without CBE (2 h, 0.5 mM). The CBE-sensitive
activity can be ascribed to the lysosomal glucocerebrosidase, and the
CBE-insensitive activity to the non-lysosomal glucosylceramidase. Af-
ter several time intervals, media samples were taken, and the fluores-
cence of the liberated 4-MU was measured.
Cultured Human Macrophages—Human macrophages were ob-
tained as described earlier (10). The deoxynojirimycin derivatives, dis-
solved in Me2SO, were added to cultured macrophages at various con-
centrations by dilution in culture medium. It was checked that the
minor amounts of Me2SO introduced in this manner were without
effect. After 4 days of preincubation with the inhibitors, in situ enzyme
activities were measured using fluorescent lipid substrates. For glu-
cosylceramidase and glucocerebrosidase activity measurement, C6-
NBD-glucosylceramide was used as substrate, and glucosylceramide
synthase activity was determined with C6-NBD-ceramide as substrate.
The lipid substrates were complexed to fatty acid-free bovine serum
albumin at a 1:1 molar ratio (11). The cells were preincubated for 2 h
with or without 300 mM CBE, washed, and incubated for 1 h with 3 ml
of medium with or without 300 mM CBE and 5 nmol of the substrate-
bovine serum albumin complex. The cells were harvested, lipids were
extracted, and the C6-NBD lipids were separated by thin-layer chroma-
tography (11). The lipids were quantified with a luminescence spec-
trometer (Perkin-Elmer LS50). Enzyme activities were related to those
in the absence of the inhibitor.
Synthesis of C6-NBD-glucosylceramide
C6-NBD-glucosylceramide was synthesized as described (12). Briefly,
glucosylsphingosine (2.17 mmol) and C6-NBD-hexanoic acid succinimi-
dylic ester (4.33 mmol) (both from Sigma) were dissolved in 530 ml of
dimethylformamide. Upon addition of 20 ml of diisopropylethylamine,
the mixture was stirred at 30 °C for several hours. Synthesis was
checked by analysis on a thin-layer plate (developing system of chloro-
form/methanol/water (65:25:4 by volume)) using ultraviolet illumina-
tion and iodine. The reaction mixture was diluted with methanol, evap-
orated under nitrogen, and analyzed on several thin-layer plates. The
separated C6-NBD-glucosylceramide was scraped off and extracted
with chloroform/methanol (1:1 by volume), chloroform/methanol (2:1 by
volume), and methanol. The supernatants were collected, evaporated,
and applied to Lichroprep RP-18 columns as described (11). C6-NBD-
glucosylceramide was eluted with methanol and chloroform/methanol
(1:1 by volume), evaporated to dryness, and dissolved in ethanol. The
concentration was determined spectrophotometrically (485 nm, e 5
20,000 units/mol/liter) and fluorometrically (excitation at 480 nm and
emission at 530 nm).
Density Gradient Electrophoresis
Melanoma cells were cultured as described above, and a crude mi-
crosome fraction was prepared from a post-nuclear supernatant exactly
as described earlier (13).
RESULTS
Design of a Specific Inhibitor for the Non-lysosomal Glucosyl-
ceramidase Activity—In a previous study (4), a number of
known glucosidase inhibitors (D-gluconolactone, castanosper-
mine, deoxynojirimycin, and N-butyldeoxynojirimycin) were
2 The abbreviations used are: DNM, deoxynojirimycin; AMP-DNM,
N-(5-adamantane-1-yl-methoxy)pentyl)-DNM; CP-DNM, N-(5-choles-
teroxypentyl)-DNM; 4-MU, 4-methylumbelliferyl; CBE, conduritol B
epoxide; C6-NBD, 6-(N-7-nitrobenz-2-oxa-1,3-diazol-4-ylaminocaproyl).
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tested with respect to their capacity to inhibit the non-lysoso-
mal glucosylceramidase. Although deoxynojirimycin was found
to be a potent inhibitor, its value was limited because, even at
low concentrations, it inhibited not only the non-lysosomal
glucosylceramidase, but also the lysosomal glucocerebrosidase
(4). Previous research has also revealed that the non-lysosomal
glucosylceramidase is tightly integrated in the membrane and
hydrolyzes its substrate glucosylceramide while it is also in-
serted in the membrane (4). These findings prompted us to
develop novel, more specific inhibitors for the non-lysosomal
glucosylceramidase, assuming that the desired inhibitor should
contain a deoxynojirimycin moiety, an N-alkyl spacer, and a
large hydrophobic group, promoting correct insertion in the
membrane. To test this concept, a series of deoxynojirimycin
derivatives was synthesized as described under “Experimental
Procedures” (Fig. 1).
In Vitro Inhibition—The inhibitory capacity and specificity
of the deoxynojirimycin-based compounds were examined by
analysis of their effects on the activity of purified human lyso-
somal glucocerebrosidase (Ceredase) and a-glucosidase and on
the activity of the lysosomal glucocerebrosidase and the non-
lysosomal glucosylceramidase as present in a membrane sus-
pension prepared from human spleen. Under “Experimental
Procedures,” the sources of the enzyme preparations and the
activity measurements are described.
Table I gives an overview of the apparent IC50 values of the
various enzymes for the deoxynojirimycin derivatives. It can be
seen that inhibition of the non-lysosomal glucosylceramidase
by the N-alkyl derivatives of deoxynojirimycin increased with
increasing chain length. Furthermore, it was found that the
presence of a carbonyl moiety (i.e. an N-acyl spacer) in the
spacer negatively influenced the inhibitory capacity.
Addition of a large hydrophobic group such as adamantane
(AMP-DNM) or cholesterol (CP-DNM) to an N-pentyl spacer
dramatically increased the capacity to inhibit the glucosylcer-
amidase activity. The apparent IC50 values for AMP-DNM and
CP-DNM are extremely low: 2 nM and 0.1 mM, respectively. For
a comparison, the IC50 values for DNM and butyl-DNM are 30
and 0.3 mM, respectively.
Table I shows that the lysosomal glucocerebrosidase is, in
general, less sensitive to inhibition by deoxynojirimycin deriv-
atives than the non-lysosomal glucosylceramidase. Pure gluco-
cerebrosidase in solution and the same enzyme associated with
splenic membranes show a different sensitivity to the inhibi-
tors. Apparently, the kinetic properties of glucocerebrosidase in
these two different states differ, as is also suggested by the
clear difference in apparent Km for 4-MU b-glucoside. Both the
purified soluble and the membrane-associated lysosomal glu-
cocerebrosidases are most potently inhibited by deoxynojirimy-
cin analogues with an N-pentyl spacer with a coupled large
hydrophobic group (Table I). With respect to the lysosomal
a-glucosidase, it was found that variation of the bulky substit-
uent in the N-alkyl series, in general, exerted relatively little
effect. However, the compounds N-(4-adamantanemethanyl-
carboxy-1-oxo)-DNM, N-(4-adamantanylcarboxy-1-oxo)-DNM,
N-(4-phenantrylcarboxy-1-oxo)-DNM, N-(4-cholesterylcarboxy-
1-oxo)-DNM, and N-(4b-cholestanylcarboxy-1-oxo)-DNM were
very poor inhibitors (Table I).
In Vivo Inhibition—The capacity of deoxynojirimycin ana-
logues to inhibit the non-lysosomal glucosylceramidase and
glucocerebrosidase activities in cultured melanoma cells was
investigated. For this purpose, cells were incubated with 4-MU
b-glucoside, and its hydrolysis by the two enzymes was deter-
mined. To distinguish between the contributions by both en-
zymes, the experiments were performed in parallel with mela-
noma cells that had been preincubated either with or without
CBE. The CBE-sensitive activity can be ascribed to the lysoso-
mal glucocerebrosidase, and the insensitive activity to the non-
lysosomal glucosylceramidase. Table II shows that again the
most potent inhibitors were found to be AMP-DNM and CP-
DNM. The non-lysosomal glucosylceramidase was very sensi-
tive to inhibition, even more pronounced than in cell homoge-
nates. For intact cells, the apparent IC50 values of AMP-DNM
and CP-DNM were ;0.3 and 50 nM, respectively. At these
concentrations, no significant inhibition of the lysosomal glu-
cocerebrosidase activity was detectable (Table II).
Next, the effects of AMP-DNM and butyl-DNM were also
examined with a more physiological lipid substrate in macro-
phages, the cells involved in glucosylceramide storage in Gau-
cher’s disease. The activity of the lysosomal glucocerebrosidase
and the non-lysosomal glucosylceramidase were measured us-
ing C6-NBD-glucosylceramide as substrate. After incubation of
the cells with the substrate, lipids were extracted and sepa-
rated by thin-layer chromatography, and the various fluores-
cently labeled metabolites were fluorometrically quantified.
Again, CBE was employed in these experiments to discriminate
between the metabolism due to the action of the non-lysosomal
glucosylceramidase and glucocerebrosidase. The result of one
of these experiments is depicted as an example in Fig. 2. It has
to be mentioned that no degradation of C6-NBD-ceramide was
detected, as observed in earlier studies (4). Apparently, C6-
NBD-ceramide is a poor substrate for the lysosomal cerami-
dase, or it leaves the lysosomes prior to degradation.
The inhibition of the activities of the lysosomal glucocerebro-
sidase and the non-lysosomal glucosylceramidase by the tested
deoxynojirimycin analogues in macrophages was comparable to
that in melanoma cells (Table III). Incubation of macrophages
with 0.05–1 nM AMP-DNM led to marked inhibition of the
FIG. 1. Nomenclature of the developed inhibitors. The structure
formulas of the deoxynojirimycin-type inhibitors are depicted. AM, ada-
mantanemethyl; A, adamantanyl; P, phenantryl; C, cholesteryl; B,
b-cholestanyl.
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non-lysosomal glucosylceramidase activity, whereas the lyso-
somal glucocerebrosidase activity was not decreased under
these conditions. In fact, we repeatedly noted a slight increase
in the activity of the lysosomal glucocerebrosidase in cells
treated with the inhibitor. Most likely, this is due to the fact
that, upon inhibition of the non-lysosomal enzyme, more sub-
strate reached the enzyme in the lysosomal compartment. Up-
regulation of the lysosomal glucocerebrosidase in cells pre-
treated with inhibitor seems unlikely since enzyme activity
was found to be increased only in intact macrophages and not
in homogenates of the same cells.
Because of the extreme sensitivity of the non-lysosomal glu-
cosylceramidase to AMP-DNM, we investigated whether the
inhibition by this compound is fully reversible. To test this,
macrophages were either treated with AMP-DNM for 1 h and
subsequently washed extensively and cultured for 9 days in the
absence of the inhibitor or long-term treated with the inhibitor.
Next, the activity of the non-lysosomal glucosylceramidase was
determined with C6-NBD-glucosylceramide as substrate. It
was observed that the 1-h treatment with inhibitor led to a
complete inhibition of the glucosylceramidase activity for at
least 9 days, suggesting that the inhibitor is not easily removed
from the enzyme or its surrounding membrane (Fig. 2).
Subcellular Localization of the Non-lysosomal Glucosylce-
ramidase—The easy access of hydrophobic AMP-DNM to the
non-lysosomal glucosylceramidase in intact cells made us to
look more closely into the localization of the enzyme using a
recently developed subcellular fractionation technique that is a
combination of density gradient centrifugation and free-flow
electrophoresis (13, 14). As shown in Fig. 3, the non-lysosomal
glucosylceramidase was recovered in fractions 30–42 of the
gradient, which are known to contain light endosomal struc-
tures. The apparent localization of the enzyme in compart-
ments close to the cell surface might explain its relatively high
sensitivity to inhibition by AMP-DNM in intact cells as com-
pared with cell homogenates. Presumably, in homogenates, a
TABLE I
Apparent IC50 values of various glycosidases
IC50 values (i.e. inhibitor concentration resulting in 50% inhibition) were determined by variation of inhibitor concentrations. Assays were
performed as described under “Experimental Procedures.” All constants are expressed in micromolar. The Km for 4-MU b-glucoside is expressed
in millimolar.
Inhibitor
IC50 values for inhibition of:
Non-lysosomal
glucosylceramidase
Glucocerebrosidase
a-Glucosidase
Ceredase Membranes
DNM 28.80 506 141 1.46
Propyl-DNM 0.12 3546 332 9.24
Butyl-DNM 0.31 912 424 6.43
Pentyl-DNM 0.038 249 8.5 3.74
Heptyl-DNM 0.028 9 13.5 1.25
Pentanoyl-DNM 84 670 83 2.39
AMC-DNMa 461 19.7 3.2 NI
AC-DNM 306 113 4.1 NI
PC-DNM 39 11.6 0.44 NI
CC-DNM NI 51.6 NI NI
BC-DNM NI 11.2 NI NI
AMP-DNM 0.0017 0.16 0.048 0.87
CP-DNM 0.097 0.96 0.77 7.20
Km 3.28 3.25 1.45 1.88
a AMC-DNM, N-(4-adamantanemethanylcarboxy-1-oxo)-DNM; AC-DNM, N-(4-adamantanylcarboxy-1-oxo)-DNM; PC-DNM, N-(4-phenantryl-
carboxy-1-oxo)-DNM; CC-DNM, N-(4-cholesterylcarboxy-1-oxo)-DNM; BC-DNM, N-(4b-cholestanylcarboxy-1-oxo)-DNM; NI, no inhibition at an
inhibitor concentration of 100 mM.
TABLE II
In vivo inhibition by deoxynojirimycin analogues
Melanoma cells were incubated with various concentrations of inhib-
itors to determine their IC50 values. Activities of glucosylceramidase
and glucocerebrosidase were determined as described (4).
Inhibitor
IC50
Non-lysosomal
glucosylceramidase Glucoccrebrosidase
nM
DNM 20,000 NIa
Propyl-DNM 650 NI
Butyl-DNM 200 NI
Pentyl-DNM 150 NI
Pentanoyl-DNM 30,000 NI
AMC-DNM 200,000 5000
AC-DNM 200,000 8000
PC-DNM 20,000 NI
AMP-DNM 0.3 100
CP-DNM 50 800
a NI, no significant inhibition detectable at 1 mM inhibitor, for other
abbreviations, see Footnote a in Table I.
FIG. 2. Inhibition of the non-lysosomal glucosylceramidase by
AMP-DNM. Cultured human macrophages were treated with AMP-
DNM, and the enzyme activities of glucocerebrosidase and the non-
lysosomal glucosylceramidase were measured using the C6-NBD-glu-
cosylceramide substrate. Lipids were extracted from the cells and
analyzed by TLC as described under “Experimental Procedures” and in
Ref. 4. A control incubation without CBE is shown in lane 1; in all other
lanes, the cells were preincubated with CBE. The following concentra-
tions of AMP-DNM were added to the cells: 1 nM (lanes 2 and 6), 0.05 nM
(lanes 3 and 7), 0.0025 nM (lanes 4 and 8). No inhibitor was added to the
cells in lane 5. The cells in lanes 2–4 were treated with AMP-DNM for
1 h after 5 days in culture and were subsequently cultured for 9 days in
the absence of AMP-DNM; the cells in lanes 6 and 7 were treated with
AMP-DNM continuously starting after 5 days in culture, and new
inhibitor was added after media changes. Markers are indicated: Cer,
ceramide; GlcCer, glucosylceramide; LacCer, lactosylceramide; SM,
sphingomyelin.
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much larger proportion of the lipophilic inhibitors is scavenged
by membrane fragments that do not contain the enzyme com-
pared with incubation of intact cells with the compounds.
Specificity of AMP-DNM as an Inhibitor of the Non-lysoso-
mal Glucosylceramidase—We studied to what extent other re-
actions were also inhibited upon incubation of intact cells with
AMP-DNM. Glucosylceramide synthase is a glucosyltrans-
ferase that catalyzes the synthesis of glucosylceramide from
ceramide and UDP-glucose. The enzyme has been reported to
be particularly sensitive to inhibition by butyl-DNM (6). Glu-
cosylceramide synthase activity was measured by incubation of
intact cells with C6-NBD-ceramide and analysis of C6-NBD-
glucosylceramide formation. In this manner, it was found that,
in agreement with the previous report (6), the IC50 value of
butyl-DNM is ;25 mM and, furthermore, that the IC50 of AMP-
DNM is 25 nM. In addition, it was observed that incubation of
melanoma cells and macrophages with 1 nM AMP-DNM did not
result in a significant reduction of glucosylceramide synthase
activity, whereas concomitantly, the non-lysosomal glucosylce-
ramidase was almost completely inhibited.
The trimming a-glucosidases in the endoplasmic reticulum
are also known to be sensitive to hydrophobic deoxynojirimycin
analogues. The effect of AMP-DNM in this respect was exam-
ined by studying the folding of influenza hemagglutinin in the
endoplasmic reticulum, as described (15). No inhibitory effect
of AMP-DNM at 1 nM on oligosaccharide chain modification
that resulted in delayed folding of influenza hemagglutinin (16)
was detectable (data not shown). Only at concentrations above
0.2 mM AMP-DNM was clear inhibition of this process detected.
DISCUSSION
Our investigation has led to the generation of potent inhib-
itors of the non-lysosomal glucosylceramidase. In particular,
AMP-DNM is an attractive compound in this respect. A com-
plete inhibition of non-lysosomal glucosylceramidase activity
occurs upon incubation of intact cells with extremely low con-
centrations of the DNM derivative. The localization of the
enzyme close to the cell surface, the design of the compound,
and its tendency to associate with membranes probably all
contribute to this. At low nanomolar concentrations, AMP-
DNM seems not to significantly affect other enzyme systems
that are sensitive to hydrophobic deoxynojirimycin analogues,
such as the glucosylceramide synthase and oligosaccharide
chain-trimming glucosidases. The compound should therefore
be useful for investigations on the non-lysosomal glucosylcer-
amidase. It will be of particular interest to study the extent to
which the enzyme activity is relevant for the lipid metabolism
coupled to signal transduction processes. Hypothetically, the
enzyme could indirectly affect the activity of neutral sphingo-
myelinase by changing the concentration of ceramide. Alterna-
tively, the enzyme itself might be involved in the conversion of
some extracellular signal into increased ceramide concentra-
tions and corresponding signaling.
Our attempts to purify the non-lysosomal glucosylcerami-
dase by conventional purification procedures have been unsuc-
cessful so far. A major complication is caused by the instability
of the enzyme upon solubilization with detergents. On the basis
of the findings made in this study, it seems attractive to exploit
the interaction of hydrophobic deoxynojirimycin analogues
with the non-lysosomal glucosylceramidase for affinity purifi-
cation of the enzyme. Previously, the lysosomal glucocerebro-
sidase and the endoplasmic reticulum a-glucosidase have been
purified on N-alkyldeoxynojirimycin derivatives immobilized
on a column matrix (17, 18). The feasibility of a comparable
approach for the non-lysosomal glucosylceramidase is cur-
rently being studied.
Another important application for the inhibitors may be
found in the field of Gaucher’s disease. In this disorder, tissue
macrophages store glucosylceramide due to the inherited defi-
ciency in lysosomal glucocerebrosidase activity (3). The abnor-
mal lipid-laden macrophages, called Gaucher’s cells, are
thought to be an essential factor in the pathophysiology of the
disease.3 These cells most likely secrete cytokines and hydro-
lases that promote tissue turnover and propagate the forma-
tion of novel storage macrophages. The mechanism by which
impaired lysosomal glucosylceramide degradation leads to ac-
tivation of the storage cells is unknown. It is conceivable that
the non-lysosomal glucosylceramidase plays an important role
in the process. Elevated concentrations of glucosylceramide in
macrophages of glucocerebrosidase-deficient individuals might
lead to increased activity of the non-lysosomal glucosylcerami-
dase. Thus, ceramide formation could be constitutively in-
creased in membranes close to the cell surface, affecting signal
transduction pathways and promoting the characteristic acti-
vation state of Gaucher’s cells. The newly developed inhibitors
should allow studies to be performed on the importance of the
non-lysosomal glucosylceramidase in this respect. If this en-
zyme activity indeed proves to be an essential factor in the
pathogenesis of Gaucher’s disease, one might consider the use
of the inhibitors in therapeutic intervention of the disorder.
Presently, Gaucher’s disease is treated by regular intravenous
infusions with large amounts of a modified human glucocere-
3 J. M. F. G. Aerts, R. G. Boot, G. H. Renkema, M. Verhoek, S. van
Weely, C. E. M. Hollak, M. H. J. van Oers, A. Erikson, and H.
Michelakakis, submitted for publication.
TABLE III
Effect of DNM analogues on cultured macrophages
Human macrophages, obtained and cultured as described (10), were
incubated with different concentrations of butyl-DNM or AMP-DNM.
After 4 days of preincubation with inhibitor, glucosylceramidase and
glucocerebrosidase activities were determined with C6-NBD-glucosyl-
ceramide as substrate (4). Enzyme activities are related to those in the
absence of inhibitor (100%).
Inhibitor Glucosylceramidaseactivity
Glucocerebrosidase
activity
% %
None 100 100
Butyl-DNM
0.5 mM 51 120
5 mM 12 112
50 mM 8 120
AMP-DNM
0.0025 nM 90 120
0.05 nM 65 115
1 nM 40 130
FIG. 3. Density gradient electrophoresis profile of the differ-
ent glucosylceramide-hydrolyzing enzymes. Density gradient
electrophoresis was performed as described under “Experimental Pro-
cedures.” The enzyme activities of b-hexosaminidase (lysosomal
marker) (M), glucocerebrosidase (E), and the non-lysosomal glucosylce-
ramidase (l) were measured in the fractions.
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brosidase (Ceredase) (19, 20). This enzyme supplementation
therapy is very successful; however, the application is re-
stricted due to the high costs. Interestingly, the use of butyl-
DNM as a therapeutic agent for Gaucher’s disease has already
been considered for a completely different reason. It has been
argued that a marked inhibition of the synthesis of glucosylce-
ramide may be beneficial for Gaucher’s disease patients since
this would result in a reduction in the amount of glucosylcer-
amide that has to be degraded by macrophages. A number of
inhibitors of glucosylceramide synthase have been proposed in
connection with this so-called substrate deprivation approach,
including 1-phenyldecanoylamino-3-morpholino-1-propanol
and its analogue 1-phenyl-2-hexadecanoylamino-3-morpholino-
1-propanol (21) and, more recently, butyl-DNM (6, 22) and the
galactose analogue, butyldeoxygalactonojirimycin (23). The re-
sults of our investigation indicate that administration of butyl-
DNM will inhibit not only glucosylceramide synthase, but also
the non-lysosomal glucosylceramidase, which is, in fact, much
more sensitive to this inhibitor. For deoxygalactonojirimycin
and N-butylgalactonojirimycin, for which inhibition of the glu-
cosylceramide synthase was also recently demonstrated, we
obtained similar results as for DNM and butyl-DNM in the
same concentration range (data not shown), indicating that the
non-lysosomal glucosylceramidase can also be inhibited by
these compounds. It can be envisioned that the combined inhi-
bition by hydrophobic deoxynojirimycin analogues of glucosyl-
ceramide synthase and the non-lysosomal glucosylceramidase
activities in Gaucher’s patients might act as a double-edged
sword since this could reduce the formation of storage cells and
inhibit the deleterious activation of these cells. In conclusion,
the newly developed hydrophobic deoxynojirimycin derivatives,
in particular AMP-DNM, have proven to be extremely potent
inhibitors of the non-lysosomal glucosylceramidase and should
be valuable research tools in the elucidation of the physiologi-
cal role of this enzyme.
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